B
LOCKADE of CD28/B7 and/or CD40/CD40L pathways has been employed with reasonable success to prevent organ allograft rejection.1.:! Additionally, contemporaneous but not discrete use of rhCfLA4-Ig and anti-CD40L monoclonal antibody (MAb) has also been shown to prevent chronic rejection.1. 3 In the realm of cellular transplantation (Tx), it has been reported that the use of either rhCfLA4-Ig or anti-CD40L MAb alone resulted in prolongation but not indefinite survival of islet allografts. 4 ,5 Based on these observations, we hypothesized that combined transient perioperative blockade of both costimulatory pathways would result in indefinite islet allograft survival, thus allowing maintenance of euglycemia in a diabetic recipient without the need for exogenous insulin. This latter tenet was tested in an MHC-incompatible mouse model of islet cell Tx; the outcome of this novel study is presented herein.
MATERIALS AND METHODS Animals and Islet Cell Tx
Inbred male DBN2 (H_2 d ) and C3H (H-2k) mice were used as donors and recipients. respectively. On day 4. the recipients were rendered diabetic by a single injection of streptozocin (STZ; 300 mg/kg; IV). Animals with documented hyperglycemia received donor islets (-600) under the left kidney capsule and their blood glucose level was sequentially monitored thereafter. In selected long-term survivors. intraperitoneal glucose tolerance test (IPGTT) was also performed. In all recipients exhibiting indefinite islet allograft survival, the graft-bearing kidney was ultimately removed. Depending on the treatment protocol, the animals were divided into five groups (Table I) .
RESULTS AND DISCUSSION
In an untreated MHC-incompatible mouse strain combination, islet allografts were rejected within 19 days' post-Tx (Table I ; Group I). Comparable survival was also witnessed when recipients were treated with isotype-matched control antibodies (Table I ; Group II). In contrast. treatment with anti-CD . . WL MAb resulted in accelerated rejection of the graft with recurrence of hyperglycemia by day 13 post-Tx iLong-surviving animals were electively sacrificed at various times post-Tx to undertake both in vivo and in vitro analyses.
( Table 1 ; Group III). Interestingly, 5/7 (71 %) of the recipients receiving rhCfLA4-Ig rejected their grafts within 26 days' post-Tx (Table 1 , Group IV); only 2/7 (29%) recipients in the latter group had graft survivals of 54 and 66 days, respectively. Nevertheless, despite the latter observation, it was evident that discrete blockade of either CD28/B7 or CD40/CD40L pathways is not sufficient to prevent islet allograft rejection. On the contrary, indefinite islet allograft survival was witnessed in recipients treated perioperatively with both rhCfLA4-Ig and anti-CD40L MAb (Table 1; Group V). Selected recipients (n = 3) from this group when subjected to IPGTI at day 50 post-Tx reversed induced hyperglycemia within 30 minutes' postg]ucose infusion.
Additionally, removal of graft-bearing kidneys in these long-term survivors was followed by demonstrable elevation in blood glucose levels to > 250 ILgldL, suggesting that the observed euglycemia was indeed maintained by transplanted islets and not by regeneration of the {3 cells in the native pancreata. Finally, these encouraging observations
